The NGVB provides a number of tests to assist eligible investigators with meeting FDA requirements for clinical gene therapy. If you know which type of testing service you'd like to request:
For a more detailed description of available tests click on the appropriate box below:
The NGVB provides cell based assays for screening vector products, transduced cell products, and post-trial monitoring for replication competent viruses.
Quantitative PCR assays for vector copy number and viral detection are available, including testing for the VSV-G, GALV, and RD114 envelope DNA.
PCR, next-generation sequencing, and bioinformatics analysis are available to eligible investigators
PERT assays for detection of reverse transcriptase is available.
The p24 ELISA assay facilitates estimation of lentiviral particle number.
For investigators conducting gene therapy research who requires FDA mandated testing, the NGVB has a number of other tests available at reduced rates.
For questions please contact the NGVB Biorepository Manager:
Lorraine Matheson
317-274-4519
